TSLPR CAR T-cell therapy: A new hope for CRLF2+ ALL, but timing of JAK inhibition is crucial
Acute lymphoblastic leukemia (ALL) with CRLF2 rearrangements in Ph-like and Down syndrome-associated ALL subtypes poses a significant challenge in pediatric oncology. These genetic abnormalities lead to constitutive signaling activation and induce resistance to conventional chemotherapy.
